Adoption of medication treatment for adolescent and young adult opioid dependence

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Adoption of medication treatment for adolescent and young adult opioid dependence"

Transcription

1 Adoptionofmedicationtreatmentforadolescent andyoungadultopioiddependence 1,2 1 MarcFishman,LawangeenKhan,ShannonGarrett1,LawrenceO Neill1, LaurenHiken1,SyedShah1,AsadBokhari1 1.MountainManorTreatmentCenter BaltimoreMD 2.JohnsHopkinsUniversitySchoolofMedicine,DeptofPsychiatry BaltimoreMD 1

2 Adoption of medication treatment for adolescent and young adult opioid dependence ABSTRACT Background. Opioid dependence in adolescents /young adults is a major public health problem. Emerging evidence suggests that medication treatments are effective in this population. This study aims to describe the implementation of medication treatment for this population in a community treatment program, and examine the association between medication use and treatment retention. Method. Data was abstracted retrospectively from clinical charts of 88 serial patients admitted between 4/08 and 10/09 to the adolescent/ young adult outpatient opioid track at Mountain Manor Treatment Center in Baltimore MD. Results. Patients were 53% male, with mean age 18.3 (range 13 21). The mean retention until 1 st dropout (defined as 2 weeks without any treatment contact) was 8.3 weeks. However return to treatment after dropout was common (42% of patients) with a mean # of interrupted treatment episodes of 2.2 (range 1 9). Cumulative mean treatment retention over all treatment episodes was 14.4 weeks (range 1 53) spanning a mean calendar time duration of 19.9 weeks (range 1 85). 42 patients (48%) were treated with buprenorphine (bup), 15 (17%) were treated with extended release injectable naltrexone (XR NTX), 3 (3%) were treated with oral naltrexone (NTX), and 27 (31%) were treated without medications. Mean cumulative retention by medication class was 17.6 weeks (range 1 43) for bup, 13.2 weeks (range 1 28) for XR NTX, 9.3 weeks (range 1 26) for no medication. Conclusions. Medication treatment for adolescent/ young adult opioid dependence is feasible in a community treatment setting. Treatment engagement followed a pattern of moving in and out of treatment, with substantial rates of return to treatment following dropout. Use of medications for relapse prevention seems to be associated with increased retention in this population in a small, non randomized sample. These very preliminary results suggest the benefits of a more longitudinal medical management model of care as compared to a more traditional model of discrete episodes of care. 2

3 Background Opioid use has risen dramatically among adolescents and young adults. Past year heroin use among 12th graders in the decade from averaged 1%, while past year non medical use of prescription opioids nearly doubled from 4.7% to 9% during the same period. 1 According to the National Survey on Drug Use and Health (NSDUH), nonmedical use of prescription drugs, which includes opiates, was the second most frequently used illicit drug among 12 to 17 year olds (3.3%) following marijuana (6.7%). This age group was second in rates of use only to the age 18 to 25 year group. 2,3 Correspondingly, treatment admissions for opioid use disorders increased 196% between Despite advances in the development of adolescent substance abuse treatments over the past decade, as well as advances in research demonstrating treatment effectiveness, 5 there is relatively little documentation of treatment outcomes among the high severity sub population of adolescent and young adult opioid users. Opioid using adolescents have very high rates of relapse and treatment dropout in outpatient treatment 6 and greater severity and worse post residential treatment outcomes compared to their non opioid using counterparts. 7 The effectiveness of relapse prevention pharmacotherapy for opioid dependence in adults is well documented, and has become the treatment standard of care. Three medications are approved by the FDA for the treatment of opioid dependence in adults the pure agonist methadone, the pure antagonist naltrexone and the partial agonist buprenorphine. However there is very little information about the use and effectiveness of pharmacotherapies for opioid dependence in adolescents and young adults. Methadone has not generally been used for adolescents because of stigma, lack of accessability, and lack of adolescent friendly treatment settings. In a Clinical Trials Network multi site trial (including our center) of adolescents and young adults (mean age =19.2 years), patients randomized to 12 weeks of buprenorphine maintenance had increased retention and decreased opioid positive urines compared to those who received 2 weeks of buprenorphine detoxification only. 9 Naltrexone has recently generated interest as a promising treatment, both as the oral formulation delivered daily under parental supervision, and as the extended release formulation delivered as a monthly injection. 3

4 Methods Clinical Treatment The treatment was conducted at Mountain Manor Treatment Center (MMTC), a community based adolescent substance abuse treatment program in Baltimore MD, which provides both residential and outpatient levels of care. The adolescent residential program is described elsewhere, 7,17 and notably includes medical/nursing staff. The outpatient program includes a Partial Hospital Program (PHP), an Intensive Outpatient Program (IOP), and a mental health clinic for concurrent treatment of comorbid psychiatric disorders. A specialized opioid dependence outpatient track was developed in September 2007 and consists of 1 2 group counseling sessions per week, 1 individual counseling session per week using manual based MET/CBT content, and physician visits typically beginning weekly then tapering to monthly. Specialty Opioid Track/Program Residential (Level III.7) Avg LOS 21 days Crisis intervention Detoxification Role induction Initiation of relapse prevention medication PHP (Level II.5) 5d/week for 1 2 weeks IOP/Outpatient (Level II.1 or I) Opioid groups (CBT) 1 2 evenings/wk Individual counseling 1x/week Physician visits weekly tapering Mental health treatment (on site) as indicated Optional attendance at general adolescent IOP 2 3 evenings/week All patients undergoing residential opioid detoxification were offered a range of alternative treatments including XR NTX, maintenance buprenorphine, oral naltrexone, and counseling treatment without medication support. Selection was based on patient and parent preference, and the clinical recommendation of a physician. Other factors influencing participation and choice of medication included ability to follow up in our outpatient clinic based on geographic distance of residence from the facility, previous experience (including success or failure, 4

5 compliance problems or diversion) with a particular medication (usually buprenorphine, which is more broadly available). Commonly cited reasons for rejecting a particular medication included: stigma against agonists (Bupe), aversion to injection (XR NTX), expense of medication and lack of insurance medication coverage (XR NTX), and lack of insurance coverage for sufficient residential length of stay to initiate treatment (XR NTX). Many patients were also treated with medications for co morbid psychiatric conditions. Buprenorphine (Bupe) Residential detox using bupe Continuation of bupe during detox (or reinstatement of bupe following detox) Weekly prescriptions for bupe as outpatient Gradually increasing prescription interval with progress Naltrexone (NTX) Residential detox using 7d bupe taper 7d period opioid free Oral NTX lead in titration Injectable extended release NTX prior to residential discharge Monthly doses of XR NTX as outpatient (or daily oral NTX with parental supervision) Participants and data collection This is a convenience sample of the 88 patients admitted to the MMTC adolescent/ young adult outpatient opioid program between 4/08 and 10/09. Data was abstracted with identifiable personal information removed from a clinical database used by clinicians to track patient care. Attendance at treatment sessions (PHP, IOP, individual or group counseling, physician visits) between 4/08 and 1/31/10 was recorded. Retention in a treatment episode was measured as weeks until dropout, which was defined as 2 consecutive weeks with no attendance at any treatment session. Attendance at a treatment session subsequent to a dropout was taken to signal the beginning of a new treatment episode. The durations of multiple treatment episodes were added together to give the cumulative treatment retention. Patients were classified in categories according to which medication (or no medication) they were treated with. The 14 patients that switched from one category to another during the course of treatment were classified by the authors (MF and LK) as belonging to the category in which they spent the longest duration of their treatment, or if the durations were roughly equivalent then by the initial category. 5

6 Results Patient characteristics Age Mean 18.3 yrs (range 13 20) Gender 53% male Treated with: Buprenorphine 48% (42) Oral Naltrexone 3% (3) XR Naltrexone 17% (17) No medications 31% (27) Switched 16% (14) Overall retention Mean (range) Retention to 1 st dropout 8.3 weeks (1 25) # of treatment episodes 2.2 (1 9) Cumulative mean retention 14.4 weeks (1 53) Calendar span of all treatment 19.9 weeks (1 85) episodes Retention by medication class Medication class Mean retention to first dropout (range) Mean cumulative retention (range) Mean calendar span all episodes (range) Buprenorphine 9.0 wks (1 32) 17.6 wks (1 43) (1 76) XR Naltrexone 7.8 wks (1 23) 13.2 wks (1 28) (1 43) No medications 7.4 wks (1 25) 9.3 wks (1 26) (1 40) 6

7 Retention by medication class 7

8 Conclusions Medication treatment for adolescent/ young adult opioid dependence is feasible in a community treatment setting. Treatment with both buprenorphine/naloxone and extended release injectable naltrexone was well tolerated and well accepted by patients and their families. The typical course of these patients was one of shifting status, moving in and out of treatment, in and out of remission and lapse/relapse. Treatment engagement followed that pattern of moving in and out of treatment, with substantial rates of return to treatment following dropout. Patient treated with medications had greater retention. Not surprisingly, drop out and relapse seemed related to medication non compliance, and parental involvement seems to be an important ingredient in enhancing compliance. The adoption of medication support as the new standard of care for opioid dependence at the treatment center has been a paradigm shift, and entailed a gradual change within the counseling treatment culture that occurred with training and direct clinical experience. While initially there had been considerable skepticism among counselors about medications used as an replacement for counseling, over time their comments emphasized the apparent utility of medications in increasing retention and making patients more available for counseling than ever before. Practical implementation issues included: the need for onsite physician and nursing staff, which were already available within the residential program and the integrated outpatient psychiatric clinic for co occurring disorders; the need for billing and utilization management infrastructure to support outpatient medical services and medication prescription; integration of the medication component into the existing psychosocial treatment infrastructure, which required the crosstraining of and support from the counselors to monitor and encourage compliance with the dosing schedules. We are finding that although medications for addiction treatment are gradually gaining acceptance, there remains some ongoing resistance to them. For example, many in the 12 Step recovery community continue to have opposition to buprenorphine. Many local half way houses will not accept our patients because of their prohibitions against buprenorphine maintenance therapy. This distinction also had considerable impact for those youth who attempt to engage in the NA fellowship as part of their continuing care. The stigma against maintenance medications persists to some extent even for naltrexone even though it is a pure antagonist, and this unfortunately remains a barrier for broader adoption. For example one patient discontinued medication then dropped out of treatment after 5 months of abstinence on XR NTX when her NA sponsor told she could not take a keychain because she was not really clean. For adolescents and young adult with opioid dependence, relapse prevention medication treatment is feasible and can be practically implemented as a standard 8

9 treatment in a community treatment program. Pharmacotherapies are easily integrated with counseling as part of a comprehensive treatment approach. Use of medications for relapse prevention seems to be associated with increased retention, especially retention with return to treatment after a first episode of care and dropout, in this population in a small, non randomized sample. These very preliminary results suggest the benefits of a more longitudinal medical management model of care as compared to a more traditional model of discrete episodes of care. 9

10 References 1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg, J.E Monitoring the Future national survey results on drug use, : Volume I, Secondary school students. National Institute on Drug Abuse, (NIH Publication No ). Bethesda, MD. 2. Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies (OAS), April 6, The NSDUH Report: Patterns and Trends in Nonmedical Prescription Pain Reliever Use: 2002 to Rockville, MD. 3. Substance Abuse and Mental Health Services Administration. (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H 32, DHHS Publication No. SMA ). Rockville, MD. 4. Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies (OAS), 2006 October 3. Admissions aged by primary substance of abuse: TEDS , Table 5.1a. Retrieved September 19, 2007, from 5. Morral AR, McCaffrey DF, Ridgeway G Effectiveness of communitybased treatment for substance abusing adolescents: 12 month outcomes of youths entering phoenix academy or alternative probation dispositions. Psychol. Addict. Behav. 18, Marsch L A, Bickel W K, Badger G J, Stothart M E, Quesnel K J, Stanger C. et al. (2005). Comparison of pharmacological treatments for opioid dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry, 62(10), Clemmey P, Payne L, Fishman M. (2004). Clinical charactertistics and treatment outcomes of adolescent heroin users. J Psychoactive Drugs 36(1): Woody GE, Poole SA, Subramaniam G. et al. (2008) Extended vs Short term Buprenorphine Naloxone for Treatment of Opioid Addicted Youth: A Randomized Trial. JAMA. 300 (17): Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Nexnanov NG, Grinenko AY, O Brien CP, Woody G.E. (2004). Naltrexone for 10

11 heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 26(4): Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, KampmanK, Dackis C, O Brien C.P (2006). Injectable, Sustained Release Naltrexone for the Treatment of Opioid Dependence. Arch Gen Psychiatry. 63: Hulse G, Morris N, Arnold Reed D, Tait R. (2009) Improving Clinical Outcomes in Treating Heroin Dependence: Randomized, Controlled Trial of Oral or Implant Naltrexone. Arch Gen Psychiatry. 66(10): Fishman M, Winstanley E, Curran E, Garrett S, Subramaniam G (2010). Treatment of Opioid Dependence in Adolescents and Young Adults With Extended Release Naltrexone: Preliminary Case Series and Feasibility. Addiction (In Press). 13. Fishman M, Clemmey P, Adger H. (2003) "Mountain Manor Treatment Center: Residential Adolescent Addictions Treatment Program." in Adolescent Substance Abuse Treatment in the United States Stevens S. and Morral A. (eds.) Haworth Press, NY,

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

Treatment of opioid use disorders

Treatment of opioid use disorders Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence

More information

Approaches to Treatment of Youth with Opioid Addiction. Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University

Approaches to Treatment of Youth with Opioid Addiction. Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University Approaches to Treatment of Youth with Opioid Addiction Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University What should we do with this case? 17 M Onset prescription opioids 15, progressing

More information

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by

More information

Update on Buprenorphine: Induction and Ongoing Care

Update on Buprenorphine: Induction and Ongoing Care Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference

More information

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine

More information

Buprenorphine Therapy in Addiction Treatment

Buprenorphine Therapy in Addiction Treatment Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition

More information

Medication-Assisted Treatment for Opioid Addiction

Medication-Assisted Treatment for Opioid Addiction Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid

More information

EPIDEMIOLOGY OF OPIATE USE

EPIDEMIOLOGY OF OPIATE USE Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months

More information

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines

More information

Opioid Treatment Services, Office-Based Opioid Treatment

Opioid Treatment Services, Office-Based Opioid Treatment Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,

More information

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System. New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high

More information

Treatment of Prescription Opioid Dependence

Treatment of Prescription Opioid Dependence Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription

More information

Medication-Assisted Addiction Treatment

Medication-Assisted Addiction Treatment Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling

More information

Prescriber Behavior, Pain Treatment and Addiction Treatment

Prescriber Behavior, Pain Treatment and Addiction Treatment Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy

More information

Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008

Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008 Treatment Episode Data Set The TEDS Report July 15, 010 Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 008 In Brief The proportion of all substance abuse treatment admissions

More information

April 23, 2015. are dependent on the nonmedical use of prescription pain medicines and heroin.

April 23, 2015. are dependent on the nonmedical use of prescription pain medicines and heroin. STATEMENT OF ROBERT L. DUPONT, MD PRESIDENT, INSTUTUTE FOR BEHAVIOR AND HEALTH, INC BEFORE THE HOUSE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS REGARDING COMBATTING THE OPIOID ABUSE EPIDEMIC: PROFESSIONAL

More information

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This

More information

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011 Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids

More information

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines

OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines Guideline Evaluation and Treatment Planning Discharge Planning Admission Criteria Continued Stay Criteria Discharge

More information

Ohio Legislative Service Commission

Ohio Legislative Service Commission Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing

More information

TRENDS IN HEROIN USE IN THE UNITED STATES: 2002 TO 2013

TRENDS IN HEROIN USE IN THE UNITED STATES: 2002 TO 2013 2013 to 2002 States: United the in Use Heroin in Trends National Survey on Drug Use and Health Short Report April 23, 2015 TRENDS IN HEROIN USE IN THE UNITED STATES: 2002 TO 2013 AUTHORS Rachel N. Lipari,

More information

Office-based Treatment of Opioid Dependence with Buprenorphine

Office-based Treatment of Opioid Dependence with Buprenorphine Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures

More information

Advances in Addiction Science and Treatment. Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014

Advances in Addiction Science and Treatment. Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014 Advances in Addiction Science and Treatment Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014 Treatment Research Research Institute, Institute, 20132012 Presentation 1. What is driving

More information

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015 Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism

Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University

More information

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen

More information

Using Drugs to Treat Drug Addiction How it works and why it makes sense

Using Drugs to Treat Drug Addiction How it works and why it makes sense Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment

More information

Opioid Dependence: Is Engaging the Receptor Necessary for Treating the Patient? Maria A. Sullivan, M.D., Ph.D.

Opioid Dependence: Is Engaging the Receptor Necessary for Treating the Patient? Maria A. Sullivan, M.D., Ph.D. Opioid Dependence: Is Engaging the Receptor Necessary for Treating the Patient? Maria A. Sullivan, M.D., Ph.D. Video: https://www.youtube.com/watch?v=pr_3-z92z0s&feature=em-upload_owner At this year s

More information

Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available

Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available Curr Psychiatry Rep (2010) 12:448 453 DOI 10.1007/s11920-010-0135-5 Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available Evgeny Krupitsky & Edwin

More information

The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA )

The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA ) The Determinations Report: A Report On the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 ( DATA ) Submitted by the Center for Substance Abuse Treatment, Substance Abuse

More information

Financial Disclosures

Financial Disclosures Opioid Agonist Therapy: To Maintain or Not To Maintain - A Case Discussion PCSS-MAT American Psychiatric Association Drs. Ed Salsitz, John Renner, Timothy Fong April 14, 2015 Financial Disclosures Edwin

More information

BUPRENORPHINE TREATMENT

BUPRENORPHINE TREATMENT BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West

More information

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification

More information

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration

More information

Allyse Adams PC, LICDC Oriana House, Inc.

Allyse Adams PC, LICDC Oriana House, Inc. Allyse Adams PC, LICDC Oriana House, Inc. 98 Heroin Overdose Deaths from 1/1/2015-7/26/2015 Last year enough narcotic pain medicines were prescribed to supply 67 pills to every man, woman and child In

More information

States In Brief Substance Abuse and Mental Health Issues At-A-Glance

States In Brief Substance Abuse and Mental Health Issues At-A-Glance virginia States In Brief Substance Abuse and Mental Health Issues At-A-Glance a Short report from the Office of applied Studies Prevalence of Illicit Substance 1 and Alcohol Use The National Survey on

More information

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of

More information

Journal of Adolescent Health 40 (2007) 477 482. Clinical observation. Manuscript received August 8, 2006; manuscript accepted November 22, 2006

Journal of Adolescent Health 40 (2007) 477 482. Clinical observation. Manuscript received August 8, 2006; manuscript accepted November 22, 2006 Journal of Adolescent Health 40 (2007) 477 482 Clinical observation Buprenorphine Replacement Therapy for Adolescents with Opioid Dependence: Early Experience from a Children s Hospital-Based Outpatient

More information

MEDICATION ASSISTED TREATMENT (MAT)

MEDICATION ASSISTED TREATMENT (MAT) MEDICATION ASSISTED TREATMENT (MAT) STATISTICS: ALCOHOL AND OPIOID USE Last year 33 Iowans died from opioid overdose deaths; an additional 19 individuals died of a heroin overdose. The number of drug overdose

More information

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for

More information

A Drug Policy for the 21st Century. Office of National Drug Control Policy

A Drug Policy for the 21st Century. Office of National Drug Control Policy A Drug Policy for the 21st Century October 18, 2014 International Nurses Society on Addictions Health Care Reform & Its Impact on Addictions Nursing: Navigating Change through the Rapids David K. Mineta,

More information

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D.

More information

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,

More information

Methadone. Buprenorphine 10/9/2015

Methadone. Buprenorphine 10/9/2015 Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious

More information

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,

More information

John R. Kasich, Governor Orman Hall, Director

John R. Kasich, Governor Orman Hall, Director John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic

More information

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,

More information

Behavioral Health Barometer. United States, 2014

Behavioral Health Barometer. United States, 2014 Behavioral Health Barometer United States, 2014 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No.

More information

Practice Protocol. Buprenorphine Guidance Protocol

Practice Protocol. Buprenorphine Guidance Protocol Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol

More information

Non medical use of prescription medicines existing WHO advice

Non medical use of prescription medicines existing WHO advice Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations

More information

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents

More information

Substance Abuse Treatment Admissions for Abuse of Benzodiazepines

Substance Abuse Treatment Admissions for Abuse of Benzodiazepines Treatment Episode Data Set The TEDS Report June 2, 2011 Substance Abuse Treatment Admissions for Abuse of Benzodiazepines Benzodiazepines are a class of central nervous system depressant drugs that are

More information

The San Francisco Office Based Opiate Treatment (OBOT) Pilot Program

The San Francisco Office Based Opiate Treatment (OBOT) Pilot Program The San Francisco Office Based Opiate Treatment (OBOT) Pilot Program Brad Shapiro, MD Medical Director And Stephen Dominy, M.D. Executive Director With Special Thanks to Dr. Alice Gleghorn and Dr. David

More information

BUPRENORPHINE TREATMENT

BUPRENORPHINE TREATMENT BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West

More information

American Society of Addiction Medicine

American Society of Addiction Medicine American Society of Addiction Medicine Public Policy Statement on Office-based Opioid Agonist Treatment (OBOT) BACKGROUND Methadone maintenance treatment of opioid addiction was developed in 1965 and implemented

More information

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry

More information

SUBSTANCE ABUSE ENCOUNTER REPORTING: HCPCS and Revenue Codes Overview of Updates for Fiscal Year 2008

SUBSTANCE ABUSE ENCOUNTER REPORTING: HCPCS and Revenue Codes Overview of Updates for Fiscal Year 2008 SUBSTANCE ABUSE ENCOUNTER REPORTING: HCPCS and Overview of Updates for Fiscal Year 2008 This encounter code and modifier chart, effective 10/1/2007, describes how submitted encounter codes and modifiers

More information

Rationale for and approach to treating Opiate Use Disorders

Rationale for and approach to treating Opiate Use Disorders Rationale for and approach to treating Opiate Use Disorders Gavin Bart, MD PhD FACP DFASAM Director, Division of Addiction Medicine Department of Medicine Hennepin County Medical Center Associate Professor

More information

States In Brief. The National Survey on Drug Use and Health. texas. Prevalence of Illicit Substance 1 and Alcohol Use

States In Brief. The National Survey on Drug Use and Health. texas. Prevalence of Illicit Substance 1 and Alcohol Use texas States In Brief Substance Abuse and Mental Health Issues At-A-Glance a short Report from the Office of applied studies Prevalence of Illicit Substance 1 and Alcohol Use The National Survey on Drug

More information

Depot Naltrexone Appears Safe and Effective for Heroin Addiction

Depot Naltrexone Appears Safe and Effective for Heroin Addiction of 2 http://www.drugabuse.gov/nida_notes/nnvol21n3/depot.html 10/20/2011 11:23 AM NIDA NEWS NIDA Home > Publications > NIDA Notes > Vol. 21, No. 3 > Research Findings Depot Naltrexone Appears Safe and

More information

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

Use of Pharmacotherapies by Substance Abuse Treatment Facilities Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1

More information

Appendix D. Behavioral Health Partnership. Adolescent/Adult Substance Abuse Guidelines

Appendix D. Behavioral Health Partnership. Adolescent/Adult Substance Abuse Guidelines Appendix D Behavioral Health Partnership Adolescent/Adult Substance Abuse Guidelines Handbook for Providers 92 ASAM CRITERIA The CT BHP utilizes the ASAM PPC-2R criteria for rendering decisions regarding

More information

Policy #: 457 Latest Review Date: December 2010

Policy #: 457 Latest Review Date: December 2010 Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Naltrexone (Vivitrol ) Injections Policy #: 457 Latest Review

More information

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Stefan P. Kruszewski, MD Board Certified in Adult, Geriatric, Adolescent and Addiction Psychiatry, and Addiction Medicine Speaker

More information

DrugFacts: Treatment Approaches for Drug Addiction

DrugFacts: Treatment Approaches for Drug Addiction DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

Re-Thinking Addiction Treatment: Have We Been Thinking Correctly?

Re-Thinking Addiction Treatment: Have We Been Thinking Correctly? Re-Thinking Addiction Treatment: Have We Been Thinking Correctly? Scope of Substance Use in the US Alcohol, Illicit & non-prescribed drugs Very Frequent Use In Specialty Treat. ~ 2,300,000 Addiction Dx

More information

Current Model of Drug Care. Components of a Full Drug Care Service

Current Model of Drug Care. Components of a Full Drug Care Service Current Model of Drug Care Treatment Detox Rehab Components of a Full Drug Care Service (1) (2) (3) (4) (5) (6) (7) (8) (9) Community Preparation Treatment Detox Rehab Community Community Prison work Halfway

More information

Testimony of The New York City Department of Health and Mental Hygiene. before the

Testimony of The New York City Department of Health and Mental Hygiene. before the Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid

More information

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate

More information

INSTRUCTIONS AND PROTOCOLS FOR THE IMPLEMENTATION OF MEDICATION-ASSISTED TREATMENT FOR OPIOID/OPIATE DEPENDENCE

INSTRUCTIONS AND PROTOCOLS FOR THE IMPLEMENTATION OF MEDICATION-ASSISTED TREATMENT FOR OPIOID/OPIATE DEPENDENCE 201 Mulholland Bay City, MI 48708 P 989-497-1344 F 989-497-1348 www.riverhaven-ca.org Title: MAT Protocol Original Date: March 30, 2009 Latest Revision Date: December 16, 2013 Approval/Release Date: January

More information

Re-Considering Addiction Treatment. Have We Been Thinking Correctly?

Re-Considering Addiction Treatment. Have We Been Thinking Correctly? Re-Considering Addiction Treatment Have We Been Thinking Correctly? Part I FDA standards of effectiveness Do substance abuse treatments meet those standards? An FDA Perspective A Drug is Approved for An

More information

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in

More information

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment Opioids for Chronic Pain and Addiction Treatment Joseph Merrill M.D., M.P.H. University of Washington February 24, 2012 Outline for Today Opioids for pain treatment Trends Problems High dose prescribing

More information

Outcomes for Opiate Users at FRN Facilities. FRN Research Report September 2014

Outcomes for Opiate Users at FRN Facilities. FRN Research Report September 2014 Outcomes for Opiate Users at FRN Facilities FRN Research Report September 2014 Introduction The illicit use of opioids has reached epidemic proportions in the United States (Alford, 2007; Meges et al,

More information

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,

More information

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff Funding Source: Grant No. 053773 Robert Wood Johnson Foundation Substance Abuse Policy Research

More information

Patients are still addicted Buprenorphine is simply a substitute for heroin or

Patients are still addicted Buprenorphine is simply a substitute for heroin or BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute

More information

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model West Virginia University School of Medicine BEHAVIORAL MEDICINE & PSYCHIATRY Morgantown, WV Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu Disclosure Reckitt Benckiser

More information

Beyond SBIRT: Integrating Addiction Medicine into Primary Care

Beyond SBIRT: Integrating Addiction Medicine into Primary Care Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison

More information

American Society of Addiction Medicine

American Society of Addiction Medicine American Society of Addiction Medicine Public Policy Statement on Treatment for Alcohol and Other Drug Addiction 1 I. General Definitions of Addiction Treatment Addiction Treatment is the use of any planned,

More information

Resources for the Prevention and Treatment of Substance Use Disorders

Resources for the Prevention and Treatment of Substance Use Disorders Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug

More information

Addiction Psychiatry Fellowship Rotation Goals & Objectives

Addiction Psychiatry Fellowship Rotation Goals & Objectives Addiction Psychiatry Fellowship Rotation Goals & Objectives Table of Contents University Neuropsychiatric Institute (UNI) Training Site 2 Inpatient addiction psychiatry rotation.....2 Outpatient addiction

More information

Provider enews TREATING PRESCRIPTION DRUG ADDICTION

Provider enews TREATING PRESCRIPTION DRUG ADDICTION Provider enews TREATING PRESCRIPTION DRUG ADDICTION Treating addiction to prescription opioids July 2012 Several options are available for effectively treating prescription opioid addiction. These options

More information

Impact of Systematic Review on Health Services: The US Experience

Impact of Systematic Review on Health Services: The US Experience Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol

More information

States In Brief Substance Abuse and Mental Health Issues At-A-Glance

States In Brief Substance Abuse and Mental Health Issues At-A-Glance kentucky States In Brief Substance Abuse and Mental Health Issues At-A-Glance A Short Report from the Office of Applied Studies Prevalence of Illicit Substance 1 and Alcohol Use The National Survey on

More information

Naltrexone for Opioid & Alcohol Use Disorders

Naltrexone for Opioid & Alcohol Use Disorders Naltrexone for Opioid & Alcohol Use Disorders Reid K. Hester, Ph.D. Director, Research Division Behavior Therapy Associates, LLC Senior Science Advisor Checkup and Choices, LLC 505.345.6100 reidkhester@gmail.com

More information

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical

More information

9/18/2013. Buprenorphine for Opioid Dependence: NIDA/SAMHSA Blending Initiative. According to the Webster Dictionary definition

9/18/2013. Buprenorphine for Opioid Dependence: NIDA/SAMHSA Blending Initiative. According to the Webster Dictionary definition 2013 Annual Conference for Behavioral Health Wichita, Kansas September 18, 2013 Alex Barajas-Muñoz, MS Buprenorphine for Opioid Dependence: A Training for Multidisciplinary Addiction Professionals NIDA/SAMHSA

More information

Medications for Alcohol and Opioid Use Disorders

Medications for Alcohol and Opioid Use Disorders Medications for Alcohol and Opioid Use Disorders Andrew J. Saxon, M.D. Center of Excellence in Substance Abuse Treatment and Education (CESATE) VA Puget Sound Health Care System Alcohol Pharmacotherapy

More information